Eli Lilly to Acquire French ADC Biotech Mablink Bioscience in Sixth Deal of the Year

Oct 18, 2023 17:03 CST Updated 17:03

Mablink Bioscience

Antibody-Drug Conjugate Developer

Eli Lilly

Global Pharmaceutical R&D and Production Company

10Month16Day,Endpoints NewsRelease exclusive information stating that,Eli Lilly and Company has agreed to acquire Mablink Bioscience S.A.S., headquartered in France.Mablink Bioscience, this is aThrough its proprietary hydrophilic drug linkerPSARlink™ Platform Develops Next-Generation Antibodies-Drug Conjugates (ADC).

According to Eli LillyChief Scientific OfficerDan SkovronskyIndicates,This is at leastMarks Eli Lilly's2023The Sixth Acquisition of the Year, increased its presence in diabetes, obesity, autoimmune diseases, and radioligand therapy asset allocation, although the company does not always disclose smaller transactions.

As for this acquisitionMablinkThe transaction, as it has not been completed yet, neither party has responded to the transaction as of the time of publication. However, it is understood that,This deal may be smaller in scale.：2022Year10Month14Day,Mablink BioscienceAnnouncement Completed3100Million EurosARound of financing will focus on antibody-drug conjugates (ADCs) for the treatment of solid tumors, particularly ovarian cancer (ADC）MBK-103Advanced to the clinical trial stage. AndAccording to the tracking of risk investment and financingPitchBookAccording to reports, the company has not raised a substantial amount of additional funds.

For Eli Lilly and Company,The deal will provide it withThe expanding oncology portfolio adds a recentITerm Assets. In fact,From2019Year80Billion-dollar acquisitionLoxoSince then, Eli LillyHas been continuously strengthening this type of pipeline asset.

Founded five years agoMablinkIt was previously stated that,It is expected to2024Began a project targeting the folic acid receptor in...ADC MBK-103Clinical Trials. Last year11Month,ImmunoGenObtainedFDAFor itsFRDrug ɑElahereAccelerated approval.

"We believe this is a possibility that could be greater thanElahere"Better drugs,"Van NaardenSaid. "The company has also built a novellinkerTechnology, we believe that this technology can be used in a variety of different projects. It actually relates toEmergence OfNectin-4 ADCUseFinishedThe same connector. Assuming the deal is completed, we will also ownlinkerTechnology, andCan make more extensive use of it.

MablinkTechnologyPSARlink"Masking" cytotoxic molecules, especially hydrophobic compounds, by adding polysarcosine chains to the linker, thereby improving pharmacological properties: making this class ofADC"Invisibility" allows them to remain in the body for a longer period, giving them more time to destroy tumor cells. Additionally, this technology can also restore the pharmacokinetics of natural antibodies.(PK) Characteristics, which enhance efficacy while avoiding damage to clearance organs such as the liver; better tolerance based onPSARlink™ADC. These improvements have increased the therapeutic index.10Times, this is a potential game-changing factor for future clinical success.

Figure:MablinkOfPSARlink™ Platform

The company'sADCPipelineMBK-103By proprietary connectors andexatecan(A potent topoisomerase-iInhibitor) as the payload design.MBK-103Targeting Folate Receptor α (FR a), a protein that is overexpressed in a variety of solid tumors.

In terms of acquisitions, according to statistics since the beginning of this year, Eli Lilly and Company previouslyThe following has been disclosed5This acquisitionTransaction:

6Month20Day, Eli Lilly andDice TherapeuticsJointly announced that they have reached an agreement, and Eli Lilly will invest approximately24Billion dollars to acquire a pharmaceutical company specializing in inflammatory diseasesDice。DiceIs a biopharmaceutical company with proprietaryDELSCAPEThe technology platform aims to develop capabilities that can impact proteins.-Protein Interaction (PPI) innovative oral small molecule drug. This acquisition is expected to be completed in2023 Q3Completed.
6Month29Day,Heidelberg PharmaAnnounce that Eli Lilly will acquireADCDeveloperEmergence Therapeutics, including minority held by its subsidiariesEmergenceShares.EmergenceIs a company focused on developingADCThe company's core pipeline is aNectin-4 ADCDrugETx-22。
6Month29Eli Lilly and Company announced its intention to acquire a cell therapy companySigilon Therapeutics, with a transaction amount as high as3.1Billion US dollars.SigilonOwnShielded Living Therapeutics™ Platform, the developed cell therapy products can produce a variety of functional or therapeutic molecules that are missing or deficient in the body, including proteins, enzymes, or other therapeutic drug molecules.
7Month14On [date], Eli Lilly and Company announced the acquisition of a company focused on cardiometabolic diseases and obesity.Versanis Bio. According to the terms of the agreement,VersanisAvailable up to19.25Hundreds of millions of dollars in cash, including upfront payments and subsequent milestone payments. The reason Eli Lilly decided to acquireVersanis, mainly because of its deep understanding of activin biology.
10Month3On [date], Eli Lilly and Company announced andPOINT Biopharma GlobalReach a final agreement, Eli Lilly will acquirePOINT. The total transaction amount is approximately14Billion USD, Premium87%。POINT Is a radiopharmaceutical company with a series of radioligand therapies in clinical and preclinical stages of development for the treatment of cancer.

References:

[1]Scoop: Eli Lilly agrees to acquire another European ADC biotech. Kyle LaHucik. October 17, 2023 06:25 PM EDTUpdated 06:51 PM.

[2]2022Year, which French rising starsBiotechWorth paying attention to?. US Stock Snowball. 2023-02-07.

[3] Public News.

—The End—